Garde Capital’s aTyr Pharma ATYR Stock Holding History

Garde Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$1.01K	–	838
2025 Q2	$1.01K	Buy	+200	New	+$787	﹤0.01%	681

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Garde Capital's ATYR Position: Q3 2025 in Review

Garde Capital sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 200 shares — an estimated $1.01K sold.

Garde Capital first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $1.01K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

Garde Capital reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 200 aTyr Pharma shares in Q3 2025, an estimated $1.01K.
Garde Capital first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
Garde Capital's aTyr Pharma position peaked at $1.01K in Q2 2025.
103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.